27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
- The FDA has approved ChemoCentryx Inc's (NASDAQ:CCXI) Tavneos (avacopan) as an adjunctive treatment for anti-neutrophil cytoplasmic autoantibody-associated vasculitis (ANCA-associated vasculitis or ANCA vasculitis).
- Related: Adcomm Split On FDA Approval For ChemoCentryx's Vasculitis Candidate.
- The approval comes for avacopan in combination with standard therapy. Avacopan is an orally administered selective complement 5a receptor inhibitor.
- ANCA vasculitis is a systemic autoimmune disease in which over-activation of the complement system further activates neutrophils, leading to inflammation and eventual destruction of small blood vessels.
- Avacopan is also approved for microscopic polyangiitis and granulomatosis with polyangiitis (the two main forms of ANCA-associated vasculitis) in Japan.
- The regulatory decision in Europe is expected by the end of 2021.
- Related content: Benzinga's Full FDA Calendar.
- Price Action: CCXI stock is up 70.50% at $33.41 during the premarket session on the last check Friday.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!